Q1 EPS Estimates for Tyra Biosciences Cut by HC Wainwright

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Equities research analysts at HC Wainwright decreased their Q1 2025 earnings estimates for Tyra Biosciences in a research note issued on Monday, March 31st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.56) for the quarter, down from their previous estimate of ($0.53). HC Wainwright currently has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.37) EPS.

TYRA has been the subject of several other research reports. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, March 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $30.83.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $8.65 on Thursday. The business has a 50-day moving average of $12.04 and a 200 day moving average of $16.08. Tyra Biosciences has a 1-year low of $8.05 and a 1-year high of $29.60. The stock has a market capitalization of $437.72 million, a PE ratio of -5.37 and a beta of 1.09.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05.

Institutional Trading of Tyra Biosciences

A number of hedge funds have recently modified their holdings of TYRA. Charles Schwab Investment Management Inc. increased its stake in shares of Tyra Biosciences by 2.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after acquiring an additional 3,792 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Tyra Biosciences during the third quarter valued at approximately $333,000. FMR LLC lifted its holdings in shares of Tyra Biosciences by 0.8% during the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after purchasing an additional 26,187 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Tyra Biosciences in the 3rd quarter worth approximately $593,000. Finally, Cinctive Capital Management LP bought a new stake in shares of Tyra Biosciences in the 3rd quarter worth approximately $538,000. Institutional investors own 84.14% of the company’s stock.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 7,779 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the transaction, the director now owns 447,857 shares in the company, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is currently owned by corporate insiders.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.